Victory Capital Management Inc. Raises Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Victory Capital Management Inc. grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 143.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,745 shares of the company's stock after acquiring an additional 17,525 shares during the quarter. Victory Capital Management Inc. owned about 0.06% of Janux Therapeutics worth $1,351,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of JANX. Mirae Asset Global Investments Co. Ltd. increased its stake in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock valued at $87,000 after purchasing an additional 339 shares in the last quarter. Amalgamated Bank increased its position in shares of Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company's stock worth $41,000 after acquiring an additional 368 shares in the last quarter. Summit Securities Group LLC acquired a new stake in shares of Janux Therapeutics in the 2nd quarter worth about $29,000. Plato Investment Management Ltd bought a new position in Janux Therapeutics in the 2nd quarter valued at about $42,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Janux Therapeutics during the 2nd quarter valued at about $151,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock traded down $0.82 on Tuesday, reaching $48.00. 457,414 shares of the company traded hands, compared to its average volume of 710,551. The firm has a market capitalization of $2.52 billion, a PE ratio of -41.03 and a beta of 3.52. The company has a 50 day moving average of $50.05 and a 200 day moving average of $45.83. Janux Therapeutics, Inc. has a 52 week low of $7.79 and a 52 week high of $65.60.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million during the quarter, compared to analysts' expectations of $1.50 million. Janux Therapeutics's quarterly revenue was down 82.6% compared to the same quarter last year. As a group, analysts anticipate that Janux Therapeutics, Inc. will post -1.34 earnings per share for the current year.

Analyst Ratings Changes

JANX has been the topic of a number of recent research reports. Wedbush restated an "outperform" rating and issued a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. Leerink Partners began coverage on shares of Janux Therapeutics in a report on Friday. They set an "outperform" rating and a $79.00 price objective on the stock. Leerink Partnrs upgraded shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a report on Thursday, November 14th. Finally, UBS Group assumed coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They issued a "buy" rating and a $69.00 price objective for the company. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Janux Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $67.70.

Insider Activity at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $46.24, for a total value of $44,297.92. Following the completion of the transaction, the insider now directly owns 6,887 shares in the company, valued at approximately $318,454.88. The trade was a 12.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the business's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the sale, the chief executive officer now directly owns 282,054 shares in the company, valued at $15,101,171.16. The trade was a 8.14 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 420,610 shares of company stock worth $19,288,666. Company insiders own 29.40% of the company's stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.